Table 2.
Mutation types of RAS/BRAF detected in 76 patients.
| Gene | Mutation | Tissue | Plasma | ||||
|---|---|---|---|---|---|---|---|
| Synchronous group | Metachronous group | Total | Synchronous group | Metachronous group | Total | ||
| KRAS | G12A, G12C, G12D, G12V, G13D, G13S |
26.32% (5/19) |
45.24% (19/42) |
39.34% (24/61) |
35.42% (17/48) |
14.29% (4/28) |
27.63% (21/76) |
| KRAS | Q61H, Q61K | 5.26% (1/19) |
0% (0/42) |
1.64% (1/61) |
0% (0/48) |
10.71% (3/28) |
3.95% (3/76) |
| KRAS | A146T | 0% (0/19) |
0% (0/42) |
0% (0/61) |
0% (0/48) |
3.57% (1/28) |
1.32% (1/76) |
| NRAS | G12V, G12D | 5.88% (1/17) |
0% (0/39) |
1.79% (1/56) |
2.08% (1/48) |
0% (0/28) |
1.32% (1/76) |
| NRAS | Q61R, Q61K | 0% (0/17) |
7.69% (3/39) |
5.36% (3/56) |
2.08% (1/48) |
0% (0/28) |
1.32% (1/76) |
| BRAF | Y472F, P403fs | 0% (0/18) |
0% (0/40) |
0% (0/58) |
2.08% (1/48) |
3.57% (1/28) |
2.63% (2/76) |
| HRAS | G12D | / | / | / | 2.08% (1/48) |
0% (0/28) |
1.32% (1/76) |
| HRAS | P167fs | / | / | / | 2.08% (1/48) |
3.57% (1/28) |
2.63% (2/76) |